Feng Lin Yang

US Patent:

20080004259, Jan 3, 2008

Filed:

Feb 3, 2006

Appl. No.:

11/795189

Inventors:

Kenneth Arrington - Philadelphia PA, US
Mark Fraley - North Wales PA, US
Robert Garbaccio - Lansdale PA, US
Shaei Huang - Lansdale PA, US
Craig Lindsley - Schwenksville PA, US
Justin Steen - Hatleysville PA, US
Feng Yang - Hatfield PA, US

International Classification:

A61K 31/416
A61K 31/41
A61K 31/4192
A61K 31/454
A61K 31/496
A61K 31/5377
A61K 31/551
A61P 35/00
C07D 211/12
C07D 231/56
C07D 243/08
C07D 249/04
C07D 257/04
C07D 403/14
C07D 413/14

US Classification:

514218000, 514234500, 514254060, 514322000, 514359000, 514381000, 514406000, 540492000, 544140000, 544371000, 546199000, 548250000, 548255000, 548362500

Abstract:

The instant invention provides for compounds which comprise substituted indolyl indazoles that inhibit CHK1 activity. The instant compounds provide a novel mechanism of action with unexpected advantageous properties; such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.